Patent · US Active

Phosphoinositide 3-kinase and Src inhibitors for treatment of pancreatic cancer

US11419872B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

Innoplexus AG · DE

Inventors

Om Sharma · Dhanbad, IN
Vijay P. Singh · Scottsdale, US
Manoj KUMAR · Longmont, US
Ishita Mallick · Pune, IN
Amit Choudhari · Pune, IN
Pulkit Anupam Srivastava · Atrauli, IN
Deepak Sharma · Kanchinakote, IN
Vivekanand Patil · Satara, IN
Priyam Singh · San Diego, US
Adity Shandilya · Patan, IN
Dinesh Solanke · Nagpur, IN

Key dates

Filing date	Jul 20, 2020
Grant date	Aug 23, 2022
Priority date	—
Expiry date	Aug 14, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/496
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A phosphoinositide 3-kinase inhibitor for use in the treatment of pancreatic cancer and a method for treatment of pancreatic cancer including administration of an phosphoinositide 3-kinase inhibitor an Src inhibitor to a human subject in need thereof. There is also provided a pharmaceutical composition comprising a phosphoinositide 3-kinase inhibitor and an Src inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.